;PMID: 7495303 ;source_file_2837.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)sentence:[e:43..116] = [t:43..116] ;2)section:[e:120..166] = [t:120..166] ;3)section:[e:170..258] = [t:170..258] ;4)sentence:[e:262..396] = [t:262..396] ;5)sentence:[e:397..590] = [t:397..590] ;6)sentence:[e:591..749] = [t:591..749] ;7)sentence:[e:750..816] = [t:750..816] ;8)sentence:[e:817..954] = [t:817..954] ;9)sentence:[e:955..1099] = [t:955..1099] ;10)sentence:[e:1100..1267] = [t:1100..1267] ;11)section:[e:1271..1315] = [t:1271..1315] ;section 0 Span:0..37 ;Am J Pathol. 1995 Dec;147(6):1790-8. (SEC (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..11] Pathol) (.:[11..12] .) (CD:[14..18] 1995) (NNP:[19..22] Dec) (::[22..23] ;) (CD:[23..26] 147) (-LRB-:[26..27] -LRB-) (CD:[27..28] 6) (-RRB-:[28..29] -RRB-) (::[29..30] :) (CD:[30..36] 1790-8) (.:[36..37] .))) ;sentence 1 Span:43..116 ;Insulin-like growth factor II in the pathogenesis of human neuroblastoma. ;[43..72]:gene-protein:"Insulin-like growth factor II" ;[102..115]:malignancy-type:"neuroblastoma" (SENT (NP-HLN (NP (NML (ADJP (NN:[43..50] Insulin) (HYPH:[50..51] -) (JJ:[51..55] like)) (NN:[56..62] growth) (NN:[63..69] factor)) (CD:[70..72] II)) (PP (IN:[73..75] in) (NP (NP (DT:[76..79] the) (NN:[80..92] pathogenesis)) (PP (IN:[93..95] of) (NP (JJ:[96..101] human) (NN:[102..115] neuroblastoma))))) (.:[115..116] .))) ;section 2 Span:120..166 ;Sullivan KA, Castle VP, Hanash SM, Feldman EL. (SEC (FRAG (NNP:[120..128] Sullivan) (NNP:[129..131] KA) (,:[131..132] ,) (NNP:[133..139] Castle) (NN:[140..142] VP) (,:[142..143] ,) (NNP:[144..150] Hanash) (NNP:[151..153] SM) (,:[153..154] ,) (NNP:[155..162] Feldman) (NNP:[163..165] EL) (.:[165..166] .))) ;section 3 Span:170..258 ;Department of Internal Medicine, University of Michigan Medical Center, Ann ;Arbor, USA. (SEC (FRAG (NNP:[170..180] Department) (IN:[181..183] of) (NNP:[184..192] Internal) (NNP:[193..201] Medicine) (,:[201..202] ,) (NNP:[203..213] University) (IN:[214..216] of) (NNP:[217..225] Michigan) (NNP:[226..233] Medical) (NNP:[234..240] Center) (,:[240..241] ,) (NNP:[242..245] Ann) (NNP:[247..252] Arbor) (,:[252..253] ,) (NNP:[254..257] USA) (.:[257..258] .))) ;sentence 4 Span:262..396 ;Insulin-like growth factor II (IGF-II) acts as an autocrine growth factor for ; many in vitro tumor cell lines including neuroblastoma. ;[262..291]:gene-protein:"Insulin-like growth factor II" ;[293..299]:gene-protein:"IGF-II" ;[312..335]:gene-protein:"autocrine growth factor" ;[382..395]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ (NP (NML (ADJP (NN:[262..269] Insulin) (HYPH:[269..270] -) (JJ:[270..274] like)) (NN:[275..281] growth) (NN:[282..288] factor)) (CD:[289..291] II)) (NP (-LRB-:[292..293] -LRB-) (NN:[293..299] IGF-II) (-RRB-:[299..300] -RRB-))) (VP (VBZ:[301..305] acts) (PP-CLR (IN:[306..308] as) (NP (DT:[309..311] an) (JJ:[312..321] autocrine) (NN:[322..328] growth) (NN:[329..335] factor))) (PP (IN:[336..339] for) (NP (NP (JJ:[341..345] many) (ADJP (FW:[346..348] in) (FW:[349..354] vitro)) (NN:[355..360] tumor) (NN:[361..365] cell) (NNS:[366..371] lines)) (PP (VBG:[372..381] including) (NP (NN:[382..395] neuroblastoma)))))) (.:[395..396] .))) ;sentence 5 Span:397..590 ;To examine the role of IGF-II in tumor biology we have analyzed a total of ;56 primary neuroblastoma tumor samples for the presence of IGF-II using a ;combination of mRNA and protein analysis. ;[421..427]:gene-protein:"IGF-II" ;[476..483]:malignancy-clinical-stage:"primary" ;[484..504]:malignancy-type:"neuroblastoma tumor" ;[533..539]:gene-protein:"IGF-II" (SENT (S (S-PRP (NP-SBJ (-NONE-:[397..397] *)) (VP (TO:[397..399] To) (VP (VB:[400..407] examine) (NP (NP (DT:[408..411] the) (NN:[412..416] role)) (PP (IN:[417..419] of) (NP (NN:[421..427] IGF-II))) (PP (IN:[428..430] in) (NP (NN:[431..436] tumor) (NN:[437..444] biology))))))) (NP-SBJ (PRP:[445..447] we)) (VP (VBP:[448..452] have) (VP (VBN:[453..461] analyzed) (NP (NP (DT:[462..463] a) (NN:[464..469] total)) (PP (IN:[470..472] of) (NP (CD:[473..475] 56) (NML (JJ:[476..483] primary) (NN:[484..497] neuroblastoma)) (NN:[499..504] tumor) (NNS:[505..512] samples)))) (PP (IN:[513..516] for) (NP (NP (DT:[517..520] the) (NN:[521..529] presence)) (PP (IN:[530..532] of) (NP (NN:[533..539] IGF-II))))) (S-MNR (NP-SBJ (-NONE-:[539..539] *)) (VP (VBG:[540..545] using) (NP (NP (DT:[546..547] a) (NN:[548..559] combination)) (PP (IN:[560..562] of) (NP (NP (NN:[563..567] mRNA) (NML-1 (-NONE-:[567..567] *P*))) (CC:[568..571] and) (NP (NN:[572..579] protein) (NML-1 (NN:[581..589] analysis)))))))))) (.:[589..590] .))) ;sentence 6 Span:591..749 ;A group of 21 samples was examined for the presence of IGF-II mRNA by slot ;blot and a separate group of 37 samples was examined for IGF-II ;immunoreactivity. ;[646..652]:gene-rna:"IGF-II" ;[724..730]:gene-protein:"IGF-II" (SENT (S (S (NP-SBJ-1 (NP (DT:[591..592] A) (NN:[593..598] group)) (PP (IN:[599..601] of) (NP (CD:[602..604] 21) (NNS:[605..612] samples)))) (VP (VBD:[613..616] was) (VP (VBN:[617..625] examined) (NP-1 (-NONE-:[625..625] *)) (PP (IN:[626..629] for) (NP (NP (DT:[630..633] the) (NN:[634..642] presence)) (PP (IN:[643..645] of) (NP (NN:[646..652] IGF-II) (NN:[653..657] mRNA))))) (PP-MNR (IN:[658..660] by) (NP (NN:[662..666] slot) (NN:[667..671] blot)))))) (CC:[672..675] and) (S (NP-SBJ-2 (NP (DT:[676..677] a) (JJ:[678..686] separate) (NN:[687..692] group)) (PP (IN:[693..695] of) (NP (CD:[696..698] 37) (NNS:[699..706] samples)))) (VP (VBD:[707..710] was) (VP (VBN:[711..719] examined) (NP-2 (-NONE-:[719..719] *)) (PP (IN:[720..723] for) (NP (NN:[724..730] IGF-II) (NN:[732..748] immunoreactivity)))))) (.:[748..749] .))) ;sentence 7 Span:750..816 ;IGF-II was detected in 48% of the total tumor specimens analyzed. ;[750..756]:gene-protein:"IGF-II" (SENT (S (NP-SBJ-1 (NN:[750..756] IGF-II)) (VP (VBD:[757..760] was) (VP (VBN:[761..769] detected) (NP-1 (-NONE-:[769..769] *)) (PP (IN:[770..772] in) (NP (NP (CD:[773..775] 48) (NN:[775..776] %)) (PP (IN:[777..779] of) (NP (NP (DT:[780..783] the) (JJ:[784..789] total) (NN:[790..795] tumor) (NNS:[796..805] specimens)) (VP (VBN:[807..815] analyzed) (NP (-NONE-:[815..815] *))))))))) (.:[815..816] .))) ;sentence 8 Span:817..954 ;IGF-II immunoreactivity was observed in cells resembling developing ;neuroblasts and was confined to the cytoplasm and proximal neurites. ;[817..823]:gene-protein:"IGF-II" (SENT (S (NP-SBJ-1 (NN:[817..823] IGF-II) (NN:[824..840] immunoreactivity)) (VP (VP (VBD:[841..844] was) (VP (VBN:[845..853] observed) (NP-1 (-NONE-:[853..853] *)) (PP-LOC (IN:[854..856] in) (NP (NP (NNS:[857..862] cells)) (VP (VBG:[863..873] resembling) (NP (VBG:[874..884] developing) (NNS:[886..897] neuroblasts))))))) (CC:[898..901] and) (VP (VBD:[902..905] was) (VP (VBN:[906..914] confined) (NP-1 (-NONE-:[914..914] *)) (PP-CLR (TO:[915..917] to) (NP (NP (DT:[918..921] the) (NN:[922..931] cytoplasm)) (CC:[932..935] and) (NP (JJ:[936..944] proximal) (NNS:[945..953] neurites))))))) (.:[953..954] .))) ;sentence 9 Span:955..1099 ;The appearance of IGF-II mRNA and protein did not correlate with tumor ;prognostic features including stage, histology, or N-myc amplification. ;[974..980]:gene-protein:"IGF-II" ;[974..980]:gene-rna:"IGF-II" ;[1079..1084]:gene-rna:"N-myc" ;[1085..1098]:variation-type:"amplification" (SENT (S (NP-SBJ (NP (DT:[955..958] The) (NN:[960..970] appearance)) (PP (IN:[971..973] of) (NP (NP (NML-1 (NN:[974..980] IGF-II)) (NN:[981..985] mRNA)) (CC:[986..989] and) (NP (NML-1 (-NONE-:[989..989] *P*)) (NN:[990..997] protein))))) (VP (VBD:[998..1001] did) (RB:[1002..1005] not) (VP (VB:[1006..1015] correlate) (PP-CLR (IN:[1016..1020] with) (NP (NP (NN:[1021..1026] tumor) (JJ:[1027..1037] prognostic) (NNS:[1039..1047] features)) (PP (VBG:[1048..1057] including) (NP (NP (NN:[1058..1063] stage)) (,:[1063..1064] ,) (NP (NN:[1065..1074] histology)) (,:[1074..1075] ,) (CC:[1076..1078] or) (NP (NN:[1079..1084] N-myc) (NN:[1085..1098] amplification)))))))) (.:[1098..1099] .))) ;sentence 10 Span:1100..1267 ;These data suggest that the expression of IGF-II is not confined to a ;specific stage of the disease but may have a broader role in the ;pathogenesis of neuroblastoma. ;[1143..1149]:gene-protein:"IGF-II" ;[1253..1266]:malignancy-type:"neuroblastoma" (SENT (S (NP-SBJ (DT:[1100..1105] These) (NNS:[1106..1110] data)) (VP (VBP:[1111..1118] suggest) (SBAR (IN:[1120..1124] that) (S (NP-SBJ-1 (NP (DT:[1125..1128] the) (NN:[1129..1139] expression)) (PP (IN:[1140..1142] of) (NP (NN:[1143..1149] IGF-II)))) (VP (VP (VBZ:[1150..1152] is) (RB:[1153..1156] not) (VP (VBN:[1157..1165] confined) (NP-1 (-NONE-:[1165..1165] *)) (PP-CLR (TO:[1166..1168] to) (NP (NP (DT:[1169..1170] a) (JJ:[1171..1179] specific) (NN:[1180..1185] stage)) (PP (IN:[1186..1188] of) (NP (DT:[1189..1192] the) (NN:[1193..1200] disease))))))) (CC:[1202..1205] but) (VP (MD:[1206..1209] may) (VP (VB:[1210..1214] have) (NP (DT:[1215..1216] a) (JJR:[1217..1224] broader) (NN:[1225..1229] role)) (PP (IN:[1230..1232] in) (NP (NP (DT:[1233..1236] the) (NN:[1237..1249] pathogenesis)) (PP (IN:[1250..1252] of) (NP (NN:[1253..1266] neuroblastoma))))))))))) (.:[1266..1267] .))) ;section 11 Span:1271..1315 ;PMID: 7495303 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1271..1275] PMID) (::[1275..1276] :) (CD:[1277..1284] 7495303) (NN:[1285..1286] -LSB-) (NNP:[1286..1292] PubMed) (::[1293..1294] -) (NN:[1295..1302] indexed) (IN:[1303..1306] for) (NNP:[1307..1314] MEDLINE) (-RRB-:[1314..1315] -RSB-)))